Status:
TERMINATED
A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Covid19
SARS-COV-2 Infection
Eligibility:
All Genders
19+ years
Phase:
PHASE3
Brief Summary
To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.
Eligibility Criteria
Inclusion
- Adults over the age of 19 as of the signed date in written consent
- Subjects in self-quarantine who contact from COVID-19 confirmed patient
- Subjects who have COVID-19 negative RT-PCR result
- Subjects with no symptoms of COVID-19
Exclusion
- Subjects who cannot orally administer the investigational products
- Subjects who need administration of immunosuppressants
- Subjects who are allergic or sensitive to investigational products or its ingredients
- Subjects who have a history of drug and/or alcohol abuse within 12 months before screening
- Subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators
Key Trial Info
Start Date :
June 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 6 2021
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04721535
Start Date
June 7 2021
End Date
October 6 2021
Last Update
December 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea